ASCO 2020：11项中国研究入选口头年度报告，17项Poster年度报告

受全球另行冠疫情制约，原定于5年末29日~6年末2日在芝加哥举行的美国政府诊疗物理学会（ASCO）年会上周将首次以线上形式举办，这是目前最大规模的线上嘉年华会。如今，大会的简述题目公布，共103个sessions，华南地区共有11项研究成果荣膺口头报告，17项荣膺Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他滨用作HER2+高血压帕金森氏症（PHOEBE）：一项III期随机试验病态。

第二场：高血压帕金森氏症

著者：华南地区医学科学院病房徐兵河任教、马飞任教，北京师范大学附属病房胡夕春任教等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴病态帕金森氏症标准规范疗程后卡培他滨维持旋律肌肉注射的III期试验病态（SYSUCC-001）。

第二场：帕金森氏症—暂时性/周边地区/专门设计疗程

著者：复旦大学防疫中心地带王树森任教等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用高血压脑的表型基本特征来数据统计分析消化道中循环DNA扫描的均值: 另行方法牵制来由对手

第二场：另行方法彻底解决来由难题

著者：郑美芹 郑德兰等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

塔纳非尼对比索拉非尼作为后半期肝脏会癌症的预备队疗程：一项解禁标记、随机、多中心地带II/III期试验病态。

第二场：呼吸道癌症—肺腹腔、癌变和锐

著者：四川大学宝兴病房毕锋任教、华南地区人民解放军八一病房秦叔逵任教等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

华南地区后半期肝癌症病患者阿帕替尼二线疗程：一项随机、安慰剂相符合、安慰剂III期研究成果

第二场：呼吸道癌症—肺腹腔、癌变和锐

著者：华南地区人民解放军八一病房秦叔逵任教、四川大学宝兴病房郑秋任教等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期住院病态卵巢癌症二次细胞会减灭术的一项随机III期试验病态：SOC1 / SGOG-OV2。

简介：内科前列腺癌症

著者：北京师范大学附属中山病房臧荣余任教等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈癌症根治病态胎盘切除术后专门设计疗程中的序贯放肌肉注射对比分开化学疗法或并行放肌肉注射（STARS研究成果）：一项随机、相符合、解禁标记的III期试验病态。

大会：内科前列腺癌症

著者：复旦大学防疫中心地带马尔季尼夫卡任教、刘继红任教等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专门设计吉非替尼对比肌肉注射用作可切除的EGFR变异的N1-N2期NSCLC-随机III期诊疗试验病态的最后总体生存统计分析。

简介：膀胱癌症—非小细胞会暂时性-周边地区/小细胞会/其他胸部

著者：佛山市人民病房吴一龙任教等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR变异寡转移非小细胞会膀胱癌症病患者预备队组氨酸激酶抑制剂联合或不联合积极最前线暂时性化学疗法：III期解禁标记诊疗随机试验病态（SINDAS）的中期结果（NCT02893332）。

简介：膀胱癌症-非小细胞会转移

著者：四川省人民病房曾铭任教等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序病态死亡-1（PD-1）的人源化IgG4单克隆抗体联合阿昔替尼用作高血压黏膜前列腺癌症病患者的Ib期研究成果的总生存期和生物标志物统计分析。

简介：前列腺癌症/皮肤癌症

著者：复旦大学病房郭军、盛锡楠任教等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可靠度和结果：通用CAR-T细胞会首次药剂试验病态疗程住院/难治病态T细胞会急病态抗原会肺炎（r/r T-ALL）的可靠度和。大会：整合中的疗程另行科技-免疫疗程。著者：王志欣等简述：3013年末历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期腹腔鳞状细胞会癌症病患者中的应用：一项随机的解禁标记II期试验病态（ORIENT-2）。大会：呼吸道癌症-肺腹腔癌症、心脏病症和锐道癌症著者：徐建明任教等简述：4511年末历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D选择病态CAR-T细胞会对髓母细胞会瘤的根除病态疗程大会：神经系统著者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、李旭东简述：2522年末历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷病患者中的应用大会：整合中的疗程学-免疫疗程著者：沈琳任教等简述：3021年末历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗程住院/难治病态ACUTE抗原会肺炎/淋巴瘤的首创药剂诊疗试验病态大会: 整合病态疗程学-免疫疗程著者简介：张明志，马如龙等简述：3026年末历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 罗勒替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合用作后半期实质瘤病患者的Ib期研究成果大会：发展病态疗程学----化学键靶向药剂和生物化学著者：龚继芳，沈琳任教等简述：3523年末历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合紫杉醇和nedaplatin疗程住院病态或高血压腹腔鳞状细胞会癌症（ESCC）病患者的II期研究成果。大会：呼吸道癌症-肺腹腔、癌变和锐道癌症的研究成果著者：王志强，郑玉红，王德申，王凤华，任超，谭琼 王志强、郑玉红、王德深、王凤华、任超、谭琼简述：4522年末历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大会：呼吸道癌症-肺腹腔癌症、心脏病症和锐管癌症的二线疗程著者：宋艳等简述：4524年末历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环RNA分类器用作初始活检时扫描高等级癌症的尿液外体环RNA分类器：一项多中心地带的回顾病态研究成果大会：脊柱生殖前列腺癌症-----癌症、脑癌症和癌症著者简介：Liaoyuan Li等简述：5522年末历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 暂时性后半期宫颈癌症并发肌肉注射后的专门设计肌肉注射大会: 内科前列腺癌症著者简介： 郑珉珉等简述：6031年末历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺髓病态癌症的相关病态：基于ALTER01031试验病态的统计分析。会话：鳞状著者：上海市病房老练任教简述：6526年末历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗程后病患者结局的制约: ALTER01031的亚组统计分析大会：鳞状著者：上海市病房老练任教简述：6527年末历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA统计分析数据统计分析I-IIIA期非小细胞会膀胱癌症（NSCLC）病患者术后住院: GASTO1035和GASTO1018的结果大会：膀胱癌症-非小细胞会暂时性-周边地区病态/小细胞会/小细胞会/其他胸科前列腺癌症著者：Si-Yu Wang等简述：9023年末历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞会膀胱癌症（NSCLC）中EGFR组氨酸激酶抑制剂的另行型MRSA机制大会:膀胱癌症-非小细胞会高血压膀胱癌症著者简介：李昕，金结缘，满宇，欧秋香，华宝，薛武，杨少，范敏 李昕、金结缘、满宇、欧秋香、华宝、薛武、杨绍、范敏简述：9528年末历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验病态中后半期前列腺癌症总生存的替代终点大会：前列腺癌症/皮肤癌症著者：聂润聪，袁书强，郑元芳，陈英波，周志伟 聂润聪、袁书强、郑元芳、陈英波、周志伟简述：10030年末历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程住院或高血压原发病态恶病态骨病患者的II期研究成果大会： 病症著者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、朱高煦、蔡启庆、涂崇奇、范正福、杨瑶简述：11525年末历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 近期评价安罗替尼在后半期病症病患者多线疗程中的可靠度和。大会：病症著者：姚伟涛，王侯强，张鹏，王志，杜另行辉，田志浩，牛晓颖 姚伟涛、王侯强、张鹏、王鑫、杜鑫辉、田志超、牛晓英简述：11526年末历：414